Cargando…

Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing

We have surveyed 191 prospectively sampled familial cancer patients with no previously detected pathogenic variant in the BRCA1/2, PTEN, TP53 or DNA mismatch repair genes. In all, 138 breast cancer (BC) cases, 34 colorectal cancer (CRC) and 19 multiple early-onset cancers were included. A panel of 4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dominguez-Valentin, Mev, Nakken, Sigve, Tubeuf, Hélène, Vodak, Daniel, Ekstrøm, Per Olaf, Nissen, Anke M., Morak, Monika, Holinski-Feder, Elke, Holth, Arild, Capella, Gabriel, Davidson, Ben, Evans, D. Gareth, Martins, Alexandra, Møller, Pål, Hovig, Eivind
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898579/ https://www.ncbi.nlm.nih.gov/pubmed/31811167 http://dx.doi.org/10.1038/s41598-019-54517-z

Ejemplares similares

Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds
por: Dominguez-Valentin, Mev, et al.
Publicado: (2018)

Identification of genetic variants for clinical management of familial colorectal tumors
por: Dominguez-Valentin, Mev, et al.
Publicado: (2018)

Personal Cancer Genome Reporter: variant interpretation report for precision oncology
por: Nakken, Sigve, et al.
Publicado: (2018)

Automated amplicon design suitable for analysis of DNA variants by melting techniques
por: Ekstrøm, Per Olaf, et al.
Publicado: (2015)

The disruptive positions in human G-quadruplex motifs are less polymorphic and more conserved than their neutral counterparts
por: Nakken, Sigve, et al.
Publicado: (2009)

Chromosomal instability and a deregulated cell cycle are intrinsic features of high‐risk gastrointestinal stromal tumours with a metastatic potential
por: Namløs, Heidi Maria, et al.
Publicado: (2023)

Disease-causing gene-flanking genomic rearrangements in HNPCC patients
por: Morak, Monika, et al.
Publicado: (2011)

Sample-Index Misassignment Impacts Tumour Exome Sequencing
por: Vodák, Daniel, et al.
Publicado: (2018)

Large-scale inference of the point mutational spectrum in human segmental duplications
por: Nakken, Sigve, et al.
Publicado: (2009)

Causes for Frequent Pathogenic BRCA1 Variants Include Low Penetrance in Fertile Ages, Recurrent De-Novo Mutations and Genetic Drift
por: Møller, Pål, et al.
Publicado: (2019)

Correction: Møller, P.; et al. Causes for Frequent Pathogenic BRCA1 Variants Include Low Penetrance in Fertile Ages, Recurrent De-Novo Mutations and Genetic Drift. Cancers 2019, 11, 132
por: Møller, Pål, et al.
Publicado: (2020)

Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines
por: Giliberto, Mariaserena, et al.
Publicado: (2022)

Splicing analyses for variants in MMR genes: best practice recommendations from the European Mismatch Repair Working Group
por: Morak, Monika, et al.
Publicado: (2022)

The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology
por: Nakken, Sigve, et al.
Publicado: (2021)

Genetic Characterization in High-Risk Individuals from a Low-Resource City of Peru
por: Zavaleta, Elizabeth, et al.
Publicado: (2022)

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
por: Aamdal, Elin, et al.
Publicado: (2021)

CellLineMiner: a knowledge portal for human cell lines
por: Nakken, Sigve, et al.
Publicado: (2012)

screenwerk: a modular tool for the design and analysis of drug combination screens
por: Hanes, Robert, et al.
Publicado: (2022)

Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database
por: Møller, Pål, et al.
Publicado: (2018)

Multigene Panel Testing for Hereditary Cancer Risk
por: Grissom, Alyssa A., et al.
Publicado: (2016)

Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing
por: Zhang, Zeng-Yun-Ou, et al.
Publicado: (2021)

Multigene tests for breast cancer: the physician’s perspective
por: Cognetti, Francesco, et al.
Publicado: (2021)

Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database
por: Møller, Pål, et al.
Publicado: (2017)

Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma
por: Davidson, Ben, et al.
Publicado: (2020)

Multigene testing of moderate-risk genes: be mindful of the missense
por: Young, E L, et al.
Publicado: (2016)

Application of Multigene Panels Testing for Hereditary Cancer Syndromes
por: Bilyalov, Airat, et al.
Publicado: (2022)

Germline multigene panel testing of patients with endometrial cancer
por: Kral, Jan, et al.
Publicado: (2023)

Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report
por: Seppälä, Toni, et al.
Publicado: (2017)

Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database
por: Møller, Pål, et al.
Publicado: (2017)

A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer
por: Sun, Li, et al.
Publicado: (2019)

Exome Sequencing and Multigene Panel Testing in 1,411 Patients With Adult-Onset Neurologic Disorders
por: Schuermans, Nika, et al.
Publicado: (2023)

The rainfall plot: its motivation, characteristics and pitfalls
por: Domanska, Diana, et al.
Publicado: (2017)

Multigene prognostic tests in breast cancer: past, present, future
por: Győrffy, Balázs, et al.
Publicado: (2015)

The Benefit of Multigene Panel Testing for the Diagnosis and Management of the Genetic Epilepsies
por: Leduc-Pessah, Heather, et al.
Publicado: (2022)

Multigene Panel Testing in Turkish Hereditary Cancer Syndrome Patients
por: ARSLAN ATES, Esra, et al.
Publicado: (2022)

Ten modifiers of BRCA1 penetrance validated in a Norwegian series
por: Heramb, Cecilie, et al.
Publicado: (2015)

Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma
por: Davidson, Ben, et al.
Publicado: (2023)

The BRCA2 variant c.68-7 T>A is associated with breast cancer
por: Møller, Pål, et al.
Publicado: (2017)

Retraction Note to: The BRCA2 variant c.68–7 T > A is associated with breast cancer
por: Møller, Pål, et al.
Publicado: (2018)

Our genes, our selves: hereditary breast cancer and biological citizenship in Norway
por: Møller, Pål, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vmueg2ankbijkem97q0saotu51